HCP
NXTC icon

Hexagon Capital Partners’s NextCure NXTC Stock Holding History

Hexagon Capital Partners’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1
Closed – – 772
2020
Q4 		$0 Buy
+1
New +$129 ﹤0.01% 739

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Hexagon Capital Partners's NXTC Position: Q1 2021 in Review

Hexagon Capital Partners sold out of NextCure (NXTC) in Q1 2021, closing a stake of 1 share.

Hexagon Capital Partners first reported a position in NXTC in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 92 funds tracked by Wall St. Rank hold NXTC as of Q1 2021.

  • Hexagon Capital Partners reported no remaining NextCure position as of Q1 2021 after selling out during the quarter.
  • Hexagon Capital Partners sold 1 NextCure share in Q1 2021.
  • Hexagon Capital Partners first reported a position in NextCure in Q4 2020 and held it in 1 quarter.
  • Hexagon Capital Partners's NextCure position peaked at $0 in Q4 2020.
  • 92 funds tracked by Wall St. Rank held NextCure as of Q1 2021.

Based on Hexagon Capital Partners's 13F filing for Q1 2021, filed 13 May 2021.